{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=37",
    "query": {
      "intervention": "Cohorting",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 11349,
    "total_pages": 1135,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T14:44:08.815Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04671173",
      "title": "Real-Time Muscle Pressure Measurements in Patients at Risk for Acute Compartment Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Compartment Syndrome"
      ],
      "interventions": [
        {
          "name": "Measurement of the Intra-Compartmental Pressure with the MY01 device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-18",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Nashville, Tennessee",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04671173"
    },
    {
      "nct_id": "NCT04060173",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout"
      ],
      "interventions": [
        {
          "name": "ABP-671",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Atom Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2019-09-05",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060173"
    },
    {
      "nct_id": "NCT03590054",
      "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Cutaneous Melanoma",
        "Stage IV Cutaneous Melanoma",
        "Locally Advanced Melanoma",
        "Locally Advanced Solid Neoplasm",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Urothelial Carcinoma",
        "Non-Small Cell Lung Carcinoma",
        "Stage IB Lung Cancer AJCC v7",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Abexinostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-08-20",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03590054"
    },
    {
      "nct_id": "NCT05487651",
      "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NHL, Relapsed, Adult",
        "B-cell Lymphoma",
        "B-cell Leukemia",
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "ALL, Adult B Cell",
        "ALL, Childhood",
        "CLL/SLL"
      ],
      "interventions": [
        {
          "name": "KUR-502",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Athenex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "3 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-10-01",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-05-18",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Portland, Oregon • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05487651"
    },
    {
      "nct_id": "NCT03126331",
      "title": "Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-03",
      "completion_date": "2023-10-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126331"
    },
    {
      "nct_id": "NCT06465745",
      "title": "ATLAS (AltaValve) Pivotal Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mitral Regurgitation",
        "Mitral Insufficiency",
        "Mitral Valve Incompetence",
        "Mitral Valve Regurgitation",
        "Mitral Incompetence"
      ],
      "interventions": [
        {
          "name": "AltaValve System.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "4C Medical Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2024-09-03",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465745"
    },
    {
      "nct_id": "NCT07402473",
      "title": "Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Early-stage Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-03-26",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 7,
      "location_summary": "Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more",
      "locations": [
        {
          "city": "Elizabeth",
          "state": "New Jersey"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07402473"
    },
    {
      "nct_id": "NCT06392269",
      "title": "A Multi-site Clinical Evaluation of Capillary Blood Samples Collected Using the Tasso+SST Device for Downstream Analyte Testing",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Serum Analytes"
      ],
      "interventions": [
        {
          "name": "Tasso+SST",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Tasso Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 443,
      "start_date": "2024-03-18",
      "completion_date": "2025-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06392269"
    },
    {
      "nct_id": "NCT04199169",
      "title": "Safety and Immunogenicity of a Nipah Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nipah Virus Infection"
      ],
      "interventions": [
        {
          "name": "HeV-sG-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Auro Vaccines LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 192,
      "start_date": "2020-02-18",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2022-11-17",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199169"
    },
    {
      "nct_id": "NCT04832854",
      "title": "A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-04-23",
      "completion_date": "2025-03-05",
      "has_results": true,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-23T14:44:08.815Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04832854"
    }
  ]
}